Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.68USD
8 Dec 2016
Change (% chg)

$0.05 (+3.07%)
Prev Close
$1.63
Open
$1.64
Day's High
$1.68
Day's Low
$1.55
Volume
144,933
Avg. Vol
232,884
52-wk High
$4.42
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

Idera Pharmaceuticals Q2 loss per share $0.11
Tuesday, 2 Aug 2016 07:00am EDT 

Idera Pharmaceuticals Inc : Q2 loss per share $0.11 . Q2 revenue $300,000 . Idera Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S .Q2 revenue view $142,000 -- Thomson Reuters I/B/E/S.  Full Article

Idera Pharmaceuticals reports Q1 loss per share $0.11
Monday, 9 May 2016 04:00pm EDT 

Idera Pharmaceuticals Inc : Idera pharmaceuticals reports first quarter 2016 financial results and provides corporate update . Q1 loss per share $0.11 .Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

Idera Pharmaceuticals Inc announces initiation of Phase 1/2 Clinical Trial of Intra-tumoral IMO-2125 in Combination With Ipilimumab in Patients With Metastatic Melanoma
Monday, 14 Dec 2015 08:00am EST 

Idera Pharmaceuticals Inc:Commenced enrollment in a Phase 1/2 clinical trial evaluating intra-tumoral IMO-2125, a TLR9 agonist in combination with ipilimumab (an anti-CTLA4 antibody) in patients with previously treated metastatic melanoma.  Full Article

Idera Pharmaceuticals, Inc intent to acquire Embarcadero
Wednesday, 7 Oct 2015 01:00pm EDT 

Idera Pharmaceuticals, Inc:Says agreement to acquire Embarcadero Technologies.Deal is expected to close in mid-Oct.  Full Article

Idera Pharmaceuticals Inc gives new preclinical data for cancer immunotherapy
Wednesday, 16 Sep 2015 09:00am EDT 

Idera Pharmaceuticals Inc:Gives new preclinical data for cancer immunotherapy with intratumoral injections of imo-2125 & in combination with ipilimumab.Says new preclinical data that showed potent and systemic anti-tumor activity in preclinical cancer models.Imo-2125 induces systemic antitumor immune response with potential to sensitize tumor microenvironment.Expects to initiate first clinical study of intratumoral imo-2125 in combination with ipilimumab in Q4.  Full Article

Idera Pharmaceuticals Inc enters into strategic clinical research alliance with MD Anderson Cancer Center
Monday, 8 Jun 2015 08:00am EDT 

Idera Pharmaceuticals Inc:Idera Pharmaceuticals enters into a strategic clinical research alliance with md Anderson cancer center to advance clinical development of intratumoral tlr9 agonist in combination with checkpoint inhibitors.Says first clinical trial of imo-2125 and checkpoint inhibitors to be initiated 2h 2015.Imo-2125 has been evaluated subcutaneously in over 80 human subjects, was well tolerated, was shown to induce immune responses.Intends to submit investigational new drug application for IMO-2125 and initiate clinical study in second half of year.  Full Article

Idera Pharmaceuticals Inc announces FDA Orphan drug designation for IMO-8400 for treatment of Diffuse Large B-Cell Lymphoma
Wednesday, 1 Apr 2015 08:30am EDT 

Idera Pharmaceuticals Inc:Says U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of endosomal Toll-like receptors (TLRs) 7, 8 and 9, for treatment of diffuse large B-cell lymphoma (DLBCL).Idera is currently conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation (ClinicalTrials.gov identifier NCT02252146).Preclinical studies have shown that in B*cell lymphomas characterized by the MYD88 L265P oncogenic mutation, including DLBCL, TLR signaling is over-activated, thereby enabling tumor cell survival and proliferation.As TLR antagonist, IMO-8400 inhibits TLR signaling.Objectives of trial are to evaluate the compound's safety, tolerability and clinical activity.Says protocol includes three dose-escalation cohorts of IMO-8400 administered subcutaneously.  Full Article

Idera Pharmaceuticals announces closing of public offering of common stock
Thursday, 19 Feb 2015 03:21pm EST 

Idera Pharmaceuticals Inc:Announced the closing of its previously announced underwritten public offering of 23,000,000 shares of common stock at an offering price of $3.75 per share.Gross proceeds to Idera from this offering total $86.25 mln, before underwriting discounts and commissions and offering expenses.Goldman, Sachs & Co. and J.P. Morgan acted as joint bookrunning managers for the offering.Piper Jaffray & Co. acted as lead manager for the offering.  Full Article

Idera Pharmaceuticals announces pricing of public offering of common stock
Friday, 13 Feb 2015 08:30am EST 

Idera Pharmaceuticals Inc:Says pricing of an underwritten public offering of 20,000,000 shares of common stock for a public offering price of $3.75 per share.The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 3,000,000 shares of common stock.All of the shares in the offering are to be sold by Idera.The offering is expected to close on or about Feb. 19, subject to customary closing conditions.The gross proceeds to Idera from this offering are expected to be about $75.0 million, before underwriting discounts and commissions and offering expenses.Idera intends to use the net proceeds from this offering, together with existing cash, cash equivalents and investments, to advance clinical development of certain of its programs.Says Goldman, Sachs & Co. and J.P. Morgan are acting as joint bookrunning managers for the offering. Piper Jaffray & Co. is acting as lead manager for the offering.  Full Article

Idera Pharmaceuticals announces proposed public offering of common stock
Monday, 9 Feb 2015 04:01pm EST 

Idera Pharmaceuticals Inc:Announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering.In connection with this offering, Idera expects to grant the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15 pct of the number of shares of common stock sold in the offering.All of the shares in the offering are to be sold by Idera.Intends to use the net proceeds from this offering, together with existing cash, cash equivalents and investments, to advance clinical development of certain of its programs.Goldman, Sachs & Co. and J.P. Morgan are acting as joint bookrunning managers for the offering.  Full Article

BRIEF-Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd enter into license agreement

* Press release - Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter into exclusive license agreement for the worldwide rights to IMO-9200